SLC4A10

Across TCGA pan-cancer cohorts, SLC4A10 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated SLC4A10 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SLC4A10 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC4A10 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, LUAD, and SCLC are the cancer types where SLC4A10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	II,III,IV	0.107	0.433	.001	21	view →
LUAD	DFS	Median	II,III,IV	0.239	0.548	.005	18	view →
SCLC	OS	Median	II,III,IV	0.247	0.670	.001	15	view →
UCEC	DFS	Median	All	0.943	0.623	.015	8	view →
LUSC	DFS	Median	All	0.425	0.718	.025	7	view →
GBM	OS	Median	All	0.020	0.416	<.001	6	view →
SARC	DFS	Median	All	0.203	0.616	.003	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

SLC4A10–LIHC (DFS)

Open the LIHC breakdown →